Please click here to check who's online and chat with them.

Covid-19 Rt-Pcr Detection Kit

Supplier From China
VERIFIED
Feb-16-22

The COVID-19 RT-PCR Detection Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal
aspirate) from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C.
263a, to perform high complexity tests.
Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper and lower respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infective status. The agent detected may not be
the definite cause of disease. Positive results do not rule out bacterial co-infection with other viruses.
Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.
The COVID-19 RT-PCR Detection Kit is intended for use by qualified trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The COVID-19 RT-PCR Detection Kit is only for use under the Food and Drug Administration's Emergency Use Authorization.

PRINCIPLE OF DETECTION
This product is a fluorescent probe-based Taqman RT-PCR assay system. Firstly, the RNA of SARS-CoV-2 will be reverse transcribed into cDNA by reverse transcriptase, and then PCR amplification will be performed with cDNA as template. During amplification of the template, the TaqMan probe will
be degraded due to the 5'-3 polymerase activity and exonuclease activity of Taq DNA polymerase, then the separation of fluorescent reporter and quencher enables the fluorescent signal to be detected by instrument. The ORF1ab gene of SARS-CoV-2 will be detected qualitatively by FAM channel, the N
gene of SARS-CoV-2 will be detected qualitatively by JOE channel, the E gene of SARS-CoV-2 will be detected qualitatively by ROX channel, and the internal reference will be detected by CY5 channel.
dUTP and UNG enzyme are used in the kit to prevent contamination of the amplified products.
Internal reference is used in the kit for quality control starting from sample collection

Price and Minimum Quantity

Price: Negotiable
MOQ: Not Specified

Recent User Reviews

This user has not received any reviews yet!

Verification Status


 
 
Contact Supplier
Renew

More Items Similiar to: Covid-19 Rt-Pcr Detection Kit

VERIFIED
Feb-16-22
 
Sample Types :
Including Nasopharyngeal swab, Oropharyngeal swab, Sputum

Controls :
Internal control, UNG enzyme and dUTP used to reduce risk of contamination, false positive and false negative results

Product Information

Upper and lower respiratory specimens such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate.

Authorized Laboratories
Laboratories certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA), 42 U.S.C. 263a, to perform high complexity tests.

About Emergency Use Authorization
(EUA)
This test (1) has not been FDA cleared or approved, (2) has been authorized by
FDA under an EUA for use by authorized laboratories, (3) has been authorized
only for the detection of nucleic acid from SARS-CoV-2, not for any other
viruses or pathogens, and (4) is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.360bbb-3(b)(1), unless the authorization
is terminated or revoked sooner.
VERIFIED
Feb-16-22
 
Indication: Qualitative detection of nucleic acid from SARS-CoV-2 in upper
and lower respiratory specimens (such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) from individuals suspected of COVID-19 by their healthcare provider.
Emergency use of this test is limited to authorized laboratories.
Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform high
complexity tests.

This letter is in response to your1 request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of your product,2 pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the
Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19.
Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.
I. Criteria for Issuance of Authorization I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:
1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition,
including severe respiratory illness, to humans infected by this virus;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and, 3. There is no adequate, approved, and available alternative to the emergency use of your
product.
4
II. Scope of Authorization
I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.
VERIFIED
Feb-16-22
 
Commodity: Covid-19 RT-PCR Detection Kit
Spec.96 tests/kit
Price:FOB SHANGHAI USD3.30/test, USD316.8/kit
$3.60/TEST CIF NY AIRPORT OR OTHER MAJOR AIRPORTS USA OR EUROPE OR S. AMERICA OR MIDDLE EAST
Payment: T/T ADVANCE 50% BALANCE BEFORE DEPARTURE OR Sight Irrevocable TRANSFERABLE LC Delivery: By AIR, 50days after receipt and confirmation of LC
May-03-20
Supplier From South Korea, South Korea (Republic Of Korea)
 
please contact me if you need Korean Rapid/RT-PCR detect Kit
(rapid: Genbody, SD biosensor, Wellsbio, Boditech, Bionote, Nanoentek)
(RT-PCR: Wellsbio, GeneMatrix, SD Biosensor)
Sep-14-20
 
USD$18.00

AccuPowe COVID-19 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 infections, detects SARS-CoV-2 (E gene and RdRp gene) RNA from a suspected infection patient's sample (such as sputum, nasopharyngeal swab, oropharyngeal swab) through Real-Time Polymerase chain reaction(PCR) using ExiStation Universal MDx system.

Validated to:
Bio-Rad CFX96
ABI 7500 Fast

Target Genes: Rdrp, E
GOLD Member
Aug-01-22

Covid-19 Test Kit

$0.50
MOQ: 20000  Pieces
Sample Available
 
Covid -19 Test Kit (Colloidal Gold Method)
For Self-testing Use (Nasal Swab)
Top 10 In China Having Ce Mark For Rapid Covid - 19 Antigen Self-test


Precise Rapid Sensitive
For At-home Testing
For Early Detection
Able To Sell Across All Eu Member States
Nov-28-23
Supplier From Hawthorn, United States
GOLD Member
Jan-05-22

New Omicron Covid Test Kit

$9
MOQ: 1300000  
Sample Available
 
Application
Suspected case test in epidemic area
Early test of fever clinic and CDC
Screening of primary medical institutions
Inspection of floating population in public areas
Performance Characterisitics
Sample tyep: nasal swab Time to result: 15-20 minutes
Sensitivity: 97.70% Specificity: 99.84% Accuracy:98.97%
Layperson study statistics
99.84% of non-professionals carried out the test without requiring assistance
99.82% of different types of results were interpreted correctly.

Parameters:
A Short Test Time: 15 mintues
B Accuracy: More than 98.1%
C Sensitivity: 96.4% Specificity: 100%
D Easy operation: Nasal Swab
E One Step solution
F Lower cost with high efficiency
G Package: 1 Test/Kit, 5 Tests/Kit, 25 Tests/Kit
H It can detection for Omicron Virus

Price and Minumum Quantity
Price FOB in USD: 1.5Minimum Order Qty: 500000 Pieces
Production Capacity: 100 Million Boxes Per WeekPackaging: 1,5,20,25,40,100,200 Pcs Per Box
Sample: Available. Sample Cost Born By Buyer
Product Model And Origin
Brand: jwfModel: jwf01
Seller Code: Jwf
Standards: Ce
Competitive Advantages
Lower cost with high efficiency
Detection for omicron virus
Easy operation
Short test time
Other Details
Omicron covid test kit
Covid test kit
Omicron test card
Covid test card
GOLD Member
Mar-20-24

Alltest Covid19 Antigen And A+B Flue Tests

$16
MOQ: 400  Pieces
Sample Available
 
Offering Alltest Covid 19 antigen + A+B flue, 1:3 combo tests, single packed, self testing, 2 years self time from my warehouse in Vilnius, Lithuania. Good price from authorised Alltest distributor.

Verification Status